Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2023 Status changed from active, no longer recruiting to discontinued due to insufficient accrual.
- 08 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.
- 22 Jul 2020 Status changed from recruiting to active, no longer recruiting.